Table 2. Results for third dose of vaccine.
| Spike antibody results | n=106 | |||
|---|---|---|---|---|
| Four-week negative | Four-week positive | Seroconversion rate | p value | |
| Baseline negative | 15 | 20 | 57% | <0.001* |
| Baseline positive | 0 | 71 | ||
| Total | 15 | 91 | ||
| Rise in spike antibody titers overall (AU/mL) | Median | IQR | ||
| Titer at baseline | 212.1 | 50–2873 | ||
| Titer at 4 weeks | 9997 | 880.7–47,063 | ||
| Rise in spike antibody titers (AU/mL) | Median | IQR | ||
| Hematologic malignancy | 2167 | 0–10,131 | <0.001* | |
| Solid malignancy | 31,010 | 9531–44,464 | ||
| Rise in spike antibody titers by solid/lymphoid/myeloid (AU/mL) | ||||
| Lymphoid cancers | 1169 | 0–8661 | <0.001* | |
| Myeloid cancers | 9424 | 4381–20,444 | ||
| Solid cancers | 31,010 | 9531–44,464 | ||
| Association with certain cancer-directed therapies | ||||
| Bruton’s tyrosine kinase inhibitors | ||||
| Change in spike antibody titers (AU/mL) | Median | IQR | ||
| Patients on BTKi (n=12) | 0 | 0–3393 | <0.001* | |
| Patients not on BTKi | 9355 | 877.3–34,410 | ||
| Anti-CD20 antibody treatment | ||||
| Change in spike antibody titers (AU/mL) | Median | IQR | ||
| Patients on CD20 (n=25) | 0 | 0–910.5 | 0.0133* | |
| Patients not on CD20 | 12735 | 2842–38,863 | ||
| Anti-CD20 antibody treatment within 6 months | Median | IQR | ||
| Yes | 0 | 0–0 | 0.05482 | |
| No | 587 | 0–4314 | ||
| Change in spike antibody titer by prior COVID infection | Median | IQR | ||
| Yes (n=9) | 19,350 | 9286–32,151 | 0.3051 | |
| No (n=96) | 6706 | 444.1–33,831 | ||
| Change in spike antibody titer by type of booster given | Median | IQR | ||
| BNT162b2 | 5534 | 433.8–18,074 | 0.09014 | |
| mRNA-1273 | 31451 | 515.5–45,057 | ||
| Change in spike antibody titer by age | Median | IQR | ||
| Age <65 years | 27451 | 2641–50,000 | 0.03438* | |
| Age ≥65 years | 6152 | 558.9–41,765 | ||
| T-cell activity | ||||
| Baseline | n=88 | % | ||
| Positive | 65 | 74% | ||
| Negative | 23 | 26% | ||
| Four-week | n=89 | |||
| Positive | 76 | 85% | ||
| Negative | 13 | 15% | ||
| Baseline neutralization activity assay (all evaluable patients, WT virus) | ||||
| Anti-S antibody negative | Anti-S antibody positive | Total | p value | |
| Neutralizing antibodies detected | 0 | 47 | 47 | <0.001 |
| Neutralizing antibodies not detected | 35 | 21 | 56 | |
| Total | 35 | 68 | 103 | |
| Four-week neutralization activity assay (all evaluable patients, WT virus) | ||||
| Anti-S antibody negative | Anti-S antibody positive | Total | p value | |
| Neutralizing antibodies detected | 0 | 77 | 77 | <0.001 |
| Neutralizing antibodies not detected | 15 | 8 | 23 | |
| Total | 15 | 85 | 100 | |
| Four-week neutralization assay (seronegative cohort 4 weeks) | n=35 | |||
| Wild type | ||||
| Negative | 19 | 54% | ||
| Positive | 16 | 46% | ||
| Omicron | ||||
| Negative | 29 | 83% | ||
| Positive | 6 | 17% |
*
Statistically significant.